OncoMatch/Clinical Trials/NCT06834529
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Is NCT06834529 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for relapsed or refractory b cell leukemia and lymphoma.
This is a single arm study to evaluate the safety and efficacy of CAR2219 CAR-T cells in the treatment of relapsed/refractory CD19/CD22 positive B cell Leukemia and Lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 positive
Required: CD22 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: rituximab or another anti-CD20 monoclonal antibody (rituximab) — B-cell lymphoma
Patients must have received rituximab or another anti-CD20 monoclonal antibody (unless Investigator determines that tumor is CD20-negative)
Must have received: anthracycline-containing chemotherapy regimen — B-cell lymphoma
Patients must have received...an anthracycline-containing chemotherapy regimen
Lab requirements
Blood counts
hgb≥70g/l
Kidney function
creatinine ≤1.5×uln
Liver function
total bilirubin ≤1.5×uln, alt and ast≤2.5×uln
Cardiac function
left ventricular ejection fraction≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify